<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Page 36</title>

    <link href="tailwind.css" rel="stylesheet" />
    <link href="styles.css" rel="stylesheet" />
    <script src="footer.js" defer></script>
    <style></style>
  </head>
  <body>
    <div
      style="
        background-color: #f2f2f4;
        display: grid;
        grid-template-columns: 3fr 2fr;
        height: 85.5vh;
        /* margin-bottom: -9.5vw; */
      "
    >
      <div
        style="
          background-color: #002068;
          padding: 3vw;
          gap: 0.5vw;
          position: relative;
          z-index: 1;
        "
        class="flex flex-col"
      >
        <div>
          <h1
            class="volta-modern-text mt-2"
            style="
              color: #f2f2f4;
              font-size: 1.3vw;
              font-weight: 100;
              line-height: 1.8vw;
            "
          >
            Leveraging Private Health Insurance to improve access for Sybrava
            <i>(Leqvio)</i>
          </h1>
          <h2
            class="mt-4"
            style="
              color: #f2f2f4;
              font-size: 1vw;
              border-radius: 100vw;
              padding: 0.1vw 0.8vw 0vw 0.8vw;
              width: max-content;
              font-weight: 600;
              background-color: #ff585d;
              margin-bottom: 1vw;
            "
          >
            Project Details/Solution
          </h2>
        </div>
        <div class="font-gray mt-6">
          <h3 class="font-bold">Clinical Value Management</h3>
          <p>
            A clinical value dossier was localised and submitted to payers. No
            health economics was done but a decision was made to have price
            parity to Repatha on year 1. This would give the payer a budget
            impact benefit vs. Repatha from year 2 onwards.
          </p>
        </div>

        <hr class="mt-2" style="color: var(--cool-gray)" />

        <div class="font-gray mt-2">
          <h3 class="font-bold">PHI Clinical Policy Unit</h3>
          <p>
            Presentation of the Sybrava value at clinical policy unity to
            empower them with knowledge on hyperlipidaemia as a diseases and the
            benefit of including Sybrava in the formulary, i.e. clinical
            efficacy and sustained lipid reduction due to better compliance
            because of the dosing schedule vs. other PSK9s.
          </p>
        </div>

        <hr class="mt-2" style="color: var(--cool-gray)" />

        <div class="font-gray mt-2">
          <p>
            The program is ongoing but we have successfully obtained formulary
            inclusion at 40% of the PHI market that has Biologics cover. We aim
            to achieve 80% by end of 2025.
          </p>
        </div>

        <hr class="mt-2" style="color: var(--cool-gray)" />
      </div>

      <div
        style="padding: 5vw; gap: 0.5vw"
        class="flex flex-col h-full justify-around"
      >
        <img
          src="./assets/SouthAfrica.png"
          width="80"
          class="absolute top-4 right-4"
        />
        <div>
          <div class="text-sm font-bold font-blue">
            Alternative Funding Model
          </div>
          <div class="button-with-icon mt-4">
            <img src="./assets/icon-money.svg" />
            <span>Special Funds</span>
          </div>
        </div>
      </div>
    </div>
    <site-footer
      style="position: relative; z-index: 100"
      next-text="Back to the List"
      next-href="page-21.html"
    ></site-footer>
  </body>
</html>
